Favipiravir was launched under the FluGuard brand at Rs 35 per pill. (Representative)
New Delhi:
Sun Pharmaceutical Industries has announced that it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per pill for the treatment of mild to moderate cases of COVID-19.
Favipiravir is the only oral antiviral therapy approved in the country for the potential treatment of patients with mild to moderate COVID-19 illness.
With more than 50,000 COVID-19 cases reported daily in India, there is an urgent need to provide more treatment options for medical professionals, said Kirti Ganorkar, CEO of India Business at Sun Pharma.
“We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continued efforts to support India’s pandemic response, ”he said in a statement.
The company will work closely with government and the medical community to ensure the availability of FluGuard to patients across the country. FluGuard stocks will be available on the market this week.
Sun Pharma is the world‘s fourth largest generic specialty pharmaceutical company and India’s leading pharmaceutical company.
Providing products to customers and patients in over 100 countries, its global presence is supported by manufacturing facilities across six continents that are approved by multiple regulatory agencies.
